share_log

BioCryst Announces FDA Acceptance Of Its New Drug Application For Oral, Once Daily ORLADEYO In Hereditary Angioedema Patents Aged 2 To 11 Years

Benzinga ·  May 14 07:02
BioCryst Announces FDA Acceptance Of Its New Drug Application For Oral, Once Daily ORLADEYO In Hereditary Angioedema Patents Aged 2 To 11 Years
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment